NICE recommends generic naftidrofuryl oxalate over Merck's branded Praxilene
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute in England and Wales, has today issued draft guidance recommending naftidrofuryl oxalate for treating intermittent claudication (cramping pains) in patients with peripheral arterial disease (PAD). Although NICE was appraising Merck Serono's brand Praxilene, the institute says that "cheaper, generic preparations" are available and should be used first.
You may also be interested in...
Real World Data Failed To Impress Kaftrio’s European Reviewers
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Australian Industry Maps Path To Better Use Of Real World Evidence
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
A First For England's NICE - Interim Review Of Spinraza Access Agreement Gets Under Way
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
Need a specific report? 1000+ reports available
Buy Reports